Structure Therapeutics, Inc.

This year has posed substantial challenges for global markets: a prolonged period of high interest rates, ongoing geopolitical instability, democratic uncertainty, and an unprecedented number of natio

The Jefferies London Healthcare Conference is now in its 15th year, and is firmly established as Europe’s biggest biopharma investment meeting. Here are some key themes to watch out for at the event,

Amgen, Inc. ’s Phase II maridebart cafraglutide (MariTide, AMG 133) has become a top priority for the company as it prepares to unveil topline Phase II data for the obesity and type 2 diabetes drug an

Eli Lilly and Company and Novo Nordisk A/S have been expanding the indications of their drugs approved to treat obesity to add to the already huge income such products have generated. Meanwhile, it